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1. INTRODUCTION
Dihydromyricetin (DHM), or ampelopsin, is a flavonoid abundantly 
present in the leaves of Ampelopsis grossedentata (Hand.-Mazz.) 
W.T. Wang (Vitaceae), which is known as Tengcha in the south of 
China and is used to prepare vine tea [1]. DHM has been reported 
to exert a number of biological and pharmacological actions, 
including anti-inflammatory activity, antioxidant activity, anti-
bacterial activity, hypoglycemic effect, hypolipidemic effect, and 
antitumor activity [2,3]. DHM is also traditionally used for the 
prevention and treatment of nephritis, hepatitis, halitosis. Studies 
have demonstrated that DHM (20 mg/kg/day) could improve 
behavioral disorders and ameliorate diabetes-related cognitive dys-
function in mice by regulation of oxidative stress [4]. For instance, 
oral administration of 600 mg/kg/day DHM for 4 weeks improved 
glucose and lipid metabolism in patients with nonalcoholic fatty 
liver disease [5]; in a hyperlipidemia mice model, DHM ameliorated 
harmful effects of hyperlipidemia on the liver [4]; DHM  treatment 
protected Streptozotocin (STZ)-induced diabetic mice against 
cardiomyopathy [6]. However, detailed pharmacological analyses 
of the mechanism of action of DHM are scarce. Therefore, in this 
study, we sought to demonstrate the potential effects of DHM on 
liver dysfunction and possible mechanisms in STZ-induced diabetic 
rats. A randomized controlled trial revealed that flavonoids, includ-
ing DHM, present in a food matrix triggered antioxidant activity 
and anti-inflammatory effects [5].
The inflammatory cytokines including Tumor Necrosis Factor-a 
(TNF-a), Interleukin-6 (IL-6), and IL-8 play important role in the 
development of diabetes-related liver inflammation [7]. Thus, all 
treatments that aimed to decrease the levels of these inflammatory 
cytokines in vivo might represent important strategies for preven-
tion of pathophysiological complications related to diabetes. It has 
also been well documented that increased oxidative stress can pro-
mote the activation of Nuclear Factor-Kappa B (NF-kB), which, 
in turn, enhances the expression of inflammatory cytokines such 
as TNF-a and IL-6 [8], therefore modulating the insulin response 
in the liver. In view of these facts, therapeutic agents that can 
strictly control blood glucose, reduce oxidative stress, and modu-
late proinflammatory cytokines are expected to be beneficial for 
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A B S T R AC T
Dihydromyricetin (DHM) dramatically improved the quality of life for Streptozotocin (STZ)-induced diabetic rats and 
significantly increased the activity of antioxidant enzymes in the liver. Moreover, DHM successfully ameliorated diabetes-
induced liver damage by suppression of apoptosis in the liver, as indicated by the decreased levels of Bax and cleaved caspase-3. 
In diabetic rats, the levels of tumor necrosis factor-a and interleukin-1b in the liver were significantly increased. However, the 
administration of DHM (100–400 mg/kg/day) for 6 weeks restored the cytokine levels to their normal values in a dose-dependent 
manner in diabetic rats by the regulation of nuclear factor-kappa B signaling pathway. In addition, DHM significantly induced 
5¢ AMP-activated protein kinase (AMPK) phosphorylation and decreased MyD88, TLR4, p38, GSK-3b protein expression levels 
in the liver of diabetic rats. In conclusion, DHM could improve STZ-induced liver impairment by preventing oxidative stress, 
apoptosis, and inflammation.
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controlling diabetic complications. Moreover, the components of 
MAPK  signaling pathway, which include p38 MAPK, participate 
in inflammation and are considered to be upstream factors of 
NF-kB [9]. The 5¢ AMP-Activated Protein Kinase (AMPK) signal-
ing pathway could modulate the inflammatory response in diabetic 
rats through regulation of the NF-kB signaling pathway.
2. MATERIALS AND METHODS
2.1. Chemicals
Dihydromyricetin and STZ were purchased from Sigma-Aldrich Co. 
(St. Louis, MO, USA). UNIQ-10 Column TRIzol Total RNA Isolation 
Kit was purchased from Sangon Biotech Co., Ltd. (Shanghai, China). 
The IL-1b, TNF-a, phospho-p38, p38, phospho-AMPK, AMPK, 
phospho-GSK-3b (Tyr216), NF-kB p65, TLR4, and MyD88  antibodies 
were obtained from Ruiying Biological Co., Ltd. (Suzhou, China). 
Secondary antibodies were bought from Sangon Biotech Co., Ltd. 
(Shanghai, China). Water, methanol, acetonitrile, and formic acid were 
purchased from CNW Technologies GmbH (Düsseldorf, Germany). 
l-2-Chlorophenylalanine was from Shanghai Hengchuang Bio-
Technology Co., Ltd. (Shanghai, China). All other laboratory chemi-
cals used in this study were of analytical grade.
2.2. Animals
Eight-week-old male Sprague-Dawley rats were supplied by Fuzhou 
General Hospital of Nanjing Military Command Animal Center 
(Fuzhou, China), and maintained in a controlled room under 
 specific-pathogen-free conditions, at constant temperature (23 ± 
2°C), humidity (50 ± 10%), and 12-h light/dark cycle (lights on at 8 
AM) at the Animal Experiment Center of Fuzhou General Hospital 
of Nanjing Military Command. All rats were fed normal chow with 
ad libitum access to water and food during the experiment. All pro-
cedures were accomplished in strict accordance with the standard 
approved by the Ethics Committee of Fuzhou General Hospital.
2.3. Induction of Diabetes Mellitus
Rats were fasted overnight prior to STZ injection. Then, diabe-
tes was induced using a single intraperitoneal injection of STZ 
(40 mg/kg body weight) dissolved in ice-cold saline as reported in 
a previous investigation [6]. Forty eight hours after STZ injection, 
the diabetic state of these rats was confirmed by measuring fast-
ing blood glucose levels (>11.1 mmol/L; URight TD-4279 Blood 
Glucose Monitoring System, Germany). The metformin and differ-
ent doses of DHM were administered by oral gavage of their aque-
ous solution (3% v/v Tween-80 in water) once a day for 6 weeks.
2.4. Experimental Procedure
Forty-two male Sprague-Dawley rats were allowed to adapt to the 
new environment for 7 days, and then were divided into six groups 
(Figure 1): normal group (normal), diabetes group (diabetic), pos-
itive group (metformin, 55 mg/kg/day), and DHM (high dose: 400 
mg/kg/day; medium dose: 200 mg/kg/day; low dose: 100 mg/kg/day). 
All groups comprised six rats, selected randomly. Rats in the 
normal group were injected with 100 mM citrate buffer (pH 4.5) 
and the others received 55 mg/kg of STZ.
2.5.  Tissue Sample Collection and  
Hematoxylin and Eosin Examination
At the end of the 6-week experiment period, the 12-h fasted rats 
were anesthetized and killed. The liver was quickly removed and 
rinsed in saline solution to remove blood, and then immediately 
frozen and stored at −80°C for various analyses. The fixed livers 
were dehydrated through graded alcohol and embedded in paraf-
fin. Then, the embedded tissues were cut into 4-μm sections and 
stained with hematoxylin and eosin (BBI, China). Histological 
images were recorded by a QCapture Pro 6.0 imaging system.
2.6. Evaluation of Antioxidant Activity
Liver tissue (1 g) was homogenized with 2.0 mL of 20 mM HEPES 
buffer. Then, 70 mM sucrose and 210 mM mannitol were fully mixed 
and centrifuged at 10,000 ́  g at 4°C for 10 min. The Superoxide 
Dismutase (SOD) activity of the supernatant was measured using the 
SOD Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) 
according to the manufacturer’s instructions. For the determination 
of Glutathione (GSH) activity, 1 g of liver was homogenized with 
2.0 mL of 50 mM Tris–HCl (containing 5 mM EDTA and 1 mM 
dithiothreitol) and fully mixed. The mixture was then centri-
fuged at 10,000 ́  g at 4°C for 20 min. The total GSH activity was 
measured using a commercial kit (Cayman Chemical Company, 
Figure 1 | Experimental protocol. Group I: normal control (vehicle 
treated); Group II: diabetic control (vehicle treated); Group III: 
diabetic rats supplemented with metformin; Groups IV, V, and VI: STZ 
hyperglycemic rats supplemented with DHM (100, 200, and 400 mg/kg 
body weight, respectively). b.w., body weight; DHM, dihydromyricetin; 
STZ, streptozotocin.
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Ann Arbor, MI, USA). Lipid peroxidation was determined as the 
amount of malondialdehyde (MDA). The method was performed 
using the MDA assay kit (Nanjing Jiancheng Bioengineering 
Institute, Nanjing, China).
2.7. Western Blot Analysis
Proteins in liver tissue were extracted with radioimmunoprecipi-
tation assay buffer and then centrifuged at 12,000 ́  g for 10 min at 
4°C. The total protein was determined by the bicinchoninic acid 
protein assay kit (Sangon Biotech, Shanghai, China). Subsequently, 
the protein extract was mixed with buffer and then boiled for 10 
min. Equal amounts of each protein were subjected to sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis for 0.5 h at 80 V, 
and then for 2.5 h at 100 V. The protein samples were subsequently 
transferred to a Merk Millipore polyvinylidene difluoride mem-
brane (Darmstadt, Germany) and then blocked with 5% skimmed 
powdered milk in Tris-buffered saline and Tween-20 (Sangon 
Biotech, Shanghai, China) for 2 h at room temperature in a shaker. 
Incubation of the primary antibodies was carried out at 4°C over-
night for NF-kB, AMPK, TNF-a, and IL-1b, followed by incubation 
with the corresponding secondary antibodies. The membrane was 
exposed to enhanced chemiluminescent reagents according to the 
manufacturer’s instructions. The Tannon imaging system was used 
to detect protein bands and the intensity of bands was quantified 
by ImageJ software (https://imagej.net/ImageJ).
2.8. Statistical Analysis
All analyses were performed in triplicate and statistical analyses 
were carried out using the Statistical Package for DPS 16.05 system 
(Zhejiang University, Hangzhou, China). The analysis of variance 
was performed at the 5% level of significance.
3. RESULTS
3.1.  Protective Effects of DHM on the  
Liver Injury
Histopathological examination of the normal liver tissue demon-
strated the healthy hepatic structure in which the lobule is made 
up of radiating plates, strands of cells forming a network around 
a central vein (Figure 2A, a and b). Liver biopsy of diabetes-induced 
rats showed moderate fibrosis, leucocyte infiltration around 
central vein indicating inflammation, dilation in central vein 
(Figure 2A, c and d), and the loss of normal architecture indicating 
liver (hepatocellular) injury. These structural characteristics were 
Figure 2 | Representative photomicrographs showing the effect of DHM and inhibition of STZ-induced liver change in diabetic rats: (A) liver of diabetic 
rat showing the loss of normal architecture with the distended portal vein, fibrosis, and leucocyte infiltration (hematoxylin and eosin-stained section);  
(B) effects of DHM on serum glycolipid metabolism (TG and TC); (C) effects of DHM on serum glycolipid metabolism (HDL-c and LDL-c); (D) effects of 
DHM on serum levels of IL-1b and TNF-a. Data are shown as mean ± standard deviation; ##p < 0.01, compared with the control (normal) group;  
*p < 0.05, **p < 0.01, compared with the vehicle group (diabetic vs. normal group). N = 6 in each group. DHM, dihydromyricetin; HDL-c, high-density 
lipoprotein-cholesterol; IL, interleukin; LDL-c, low-density lipoprotein-cholesterol; Met, metformin; STZ, streptozotocin; TC, total cholesterol; TG, total 
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less pronounced in diabetic animals administered either  metformin 
(Figure 2A, e and f) or DHM (Figure 2A, g and h). By contrast, 
as shown in Figure 2B, hepatic cholesterol (total cholesterol) and 
hepatic triglyceride (total triglyceride) levels were significantly 
(p < 0.05) decreased at the DHM dose of 400 mg/kg, compared with 
the diabetes group. DHM also significantly (p < 0.01) decreased 
the low-density lipoprotein-cholesterol level and increased the 
high-density lipoprotein-cholesterol level (Figure 2C). In addi-
tion, as shown in Figure 2D, both TNF-a and IL-1b levels were 
significantly increased in the diabetes group in comparison with 
the normal group. Both DHM and metformin obviously decreased 
TNF-a and IL-1b levels in serum (p < 0.01). Values of TNF-a 
and IL-1b expression obtained after treatment with metformin or 
DHM were not statistically different.
3.2.  DHM Protected the Liver of Diabetic 
Rats from Oxidative Stress
To gain insights into the beneficial effects of DHM on the liver 
of diabetic rats, we evaluated the ability of DHM to increase both 
enzymatic SOD activity and GSH levels, as well as to decrease MDA 
levels. Data obtained are presented in Table 1. The diabetic group 
showed a significant decrease in SOD activity (175.78 ± 27.00 
U/mg prot, p < 0.001) and GSH levels (25.42 ± 5.41 mg/g prot, 
p < 0.001) compared with the control group. Meanwhile, an  elevated 
MDA level (7.68 ± 1.71 nmol/g prot, p < 0.001) in the diabetic liver 
tissue was confirmed. However, DHM supplementation signifi-
cantly restored SOD activity (251.35 ± 69.03 U/mg prot at a dose 
of 100 mg/kg) (p < 0.01) and GSH levels (28.19 ± 9.22 mg/g prot, 
p < 0.01) compared with nontreated diabetic rats. Furthermore, 
DHM significantly reversed the increase of lipid peroxidation in 
STZ-induced diabetic rats, as indicated by the reduction in MDA 
levels (from 7.68 to 4.72 nmol/g prot at a dose of 400 mg/kg).
3.3.  DHM Inhibited STZ-induced Apoptosis 
in Liver
Streptozotocin is known to induce apoptosis of b-cells [10,11]. 
To reveal whether DHM could inhibit STZ-induced apoptosis in 
the liver of rat, we measured the protein expressions of Bcl-2, Bax, 
and caspase-3. As shown in Figure 3, STZ injection significantly 
Table 1 | Dihydromyricetin suppresses streptozotocin-induced oxidative 









Normal 230.10 ± 33.03# 34.27 ± 6.09# 4.79 ± 0.81#
Diabetic 175.78 ± 27.00* 25.42 ± 5.41* 7.68 ± 1.71*
Diabetic + metformin 201.27 ± 29.62 30.40 ± 3.37# 5.50 ± 1.06#
Diabetic + high dose 222.87 ± 29.20# 31.18 ± 2.11# 4.72 ± 0.87#
Diabetic +  
medium dose
195.58 ± 15.51 29.66 ± 7.161 7.60 ± 1.13#
Diabetic + low dose 251.35 ± 69.03# 28.19 ± 9.22## 6.10 ± 0.85**
Data are reported as mean ± standard error. Statistical significance was analyzed by the 
generalized linear model followed by analysis of variance. #p < 0.05, ##p < 0.01, compared 
with normal control; *p < 0.05, **p < 0.01, compared with the vehicle group (diabetic vs. 
normal group). N = 6 for each group. MDA, malondialdehyde.
Figure 3 | DHM inhibited STZ-induced apoptosis in the liver of rats. (A) Western blot analysis of the Bax, Bcl-2, and caspase-3 proteins in the liver. 
Relative density analysis of the (B) Bax protein bands, (C) Bcl-2 protein bands, and (D) cleaved caspase-3 protein bands. b-Actin was probed as an  
internal control in the relative density analysis. The vehicle control is set as 1.0. Values are averages from three independent experiments. Data are shown 
as mean ± standard deviation; ##p < 0.01, compared with the control (normal) group; *p < 0.05, **p < 0.01, compared with the vehicle group (diabetic vs. 
normal group). N = 6 in each group. DHM, dihydromyricetin; Met, metformin; STZ, streptozotocin.
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increased the expression levels of Bax and caspase-3, but decreased 
the expression level of Bcl-2, compared with the control group. 
However, treatment with DHM effectively blocked STZ-induced 
changes in these apoptotic proteins.
3.4.  Effect of DHM on the Levels of TLR4 
and MyD88 in Liver
Activation of the TLR4 and MyD88 pathways could induce exces-
sive expression of inflammatory cytokines [12]. In this study, the 
protein expression of TLR4 (Figure 4A) and MyD88 (Figure 4B) 
was remarkably upregulated in the livers of STZ-induced diabetic 
rats. However, DHM significantly decreased these protein expres-
sion levels in the diabetic group (p < 0.01).
3.5. DHM Affected the Level of NF-jB
As presented in Figure 4C, the expression level of p-NF-kB in the 
STZ-induced diabetes group was markedly higher than in the other 
groups. Figure 4A and 4B showed that the total content of TLR4 
in liver tissues was significantly higher in the STZ-induced diabe-
tes group compared with other groups. Our results further showed 
that DHM could inhibit the lipopolysaccharide-activated TLR4–
NF-kB pathway.
3.6. DHM Impacted the Level of AMPK
5¢ AMP-activated protein kinase was reported to be involved in 
 oxidative stress and chronic inflammatory disorders. We next 
examined whether DHM could inhibit STZ-induced liver damage 
via AMPK activation. STZ exposure significantly suppressed 
AMPK phosphorylation in the rat liver (p < 0.01). However, treat-
ment with DHM restored the decreased phosphorylation levels of 
AMPK to normal levels (Figure 4D).
3.7.  DHM Mediated the Protective Effects 
through GSK-3a and p38 Pathways
GSK-3b and p38 MAPK play important roles in inflammation and 
apoptosis. Thus, we also measured the phosphorylation levels of 
GSK-3b and p38 (Figure 5). We observed that the protein phosphor-
ylation of GSK-3b (Tyr216) and p38 was reduced as a result of STZ 
exposure, whereas oral administration of DHM markedly inhibited 
the phosphorylation levels of GSK-3b (Tyr216) and p38 (p < 0.01).
4. DISCUSSION
In this study, DHM ameliorated impairments by regulating the 
expression of AMPK, NF-kB, TLR4, MyD88, p38, and GSK-3b 
Figure 4 | DHM decreased the levels of TLR4, MyD88, NF-kB, and AMPK phosphorylation in the liver of rats. Relative density analysis of the (A) TLR4 
protein bands, (B) MyD88 protein bands, (C) NF-kB protein bands, and (D) AMPK protein bands. b-Actin was probed as an internal control in the 
relative density analysis. The vehicle control is set as 1.0. Values are averages from three independent experiments. Data are shown as mean ± standard 
deviation; ##p < 0.01,  compared with the control (normal) group; **p < 0.01, compared with the vehicle group (diabetic vs. normal group). N = 6 in each 
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in rats. Diabetes is characterized by insulin resistance, which is 
associated with hyperglycemia. To maintain glucose homeostasis, 
a complex mechanism is involved in glucose uptake and produc-
tion. In this regard, liver always plays a key role in modulating 
glucose metabolism, including in glycolysis, gluconeogenesis, 
glycogenolysis, and glycogenesis. It is well known that secretion 
of inflammatory cytokines is associated with insulin sensitivity, 
thus, diabetic patients typically have comparatively high levels of 
TNF-a and IL-1b. To elucidate the underlying mechanism of the 
anti- inflammatory potential of DHM, genetic approaches were 
used in this study (Figure 2). As mentioned earlier, TNF-a and IL-6 
are key factors that influence diabetic status, with increase in TNF-
a negatively affecting insulin signal transduction. TNF-a activates 
signaling pathways associated with cell survival, apoptosis, inflam-
matory response, and cell differentiation. In addition, TNF-a is 
involved in the regulation of IL-1b expression, induction of acute 
phase response, and NF-kB p65 activation. We noted increases in 
the TNF-a and IL-1b expression in the liver of STZ-induced dia-
betic rats. The result presented here indicated that increased TNF 
and IL levels were elevated by DHM. Several lines of evidence show 
a close link between oxidative stress and inflammation [13,14]. 
STZ can induce extensive Reactive Oxygen Species (ROS) forma-
tion, which may cause damage to proteins, lipids, and DNA [15]. 
In the next stage of our experiment, we found that DHM treatment 
significantly improved glucose homeostasis through enhancement 
of insulin secretion in STZ-induced diabetic rats (data not shown). 
Six weeks of daily treatment with DHM dramatically improved the 
quality of life for diabetic rats by decreasing plasma glucose and 
increasing plasma insulin. In addition, DHM was found to signifi-
cantly alleviate liver damage in diabetic rats. The underlying mech-
anism related to this antidiabetic action might be due to both liver 
protection and anti-inflammatory action. The first mechanism 
responsible for the protective action of DHM was the upregulation 
of SOD and GSH activities in the liver, resulting in lower levels of 
MDA (Table 1). By regulating the balance of defense enzymes that 
catalyze the transformation of singlet oxygen into H2O2, the cellular 
constituents are protected from oxidative damage. It is well known 
that oxidative stress plays an important role in the development of 
injury caused by diabetes and these injuries are exacerbated in dia-
betes. Several investigators have reported that SOD concentration 
is decreased in patients with type 2 diabetes [14]. Treatment with 
DHM improved the activities of SOD and therefore ameliorated 
tissue damage in diabetic rats. The activity of GSH in the liver of 
diabetic rats was also significantly inhibited (p < 0.01). GSH can 
reduce the scavenging rate of H2O2 and endorses hydroxyl rad-
ical formation which leads to more internal radicals. Treatment 
with DHM increased hepatic GSH level in diabetic rats. Thus, the 
improved SOD and GSH levels likely resulted in inhibition of oxi-
dative stress. In addition, MDA levels in the diabetic group were 
significantly increased compared with the normal group, indicat-
ing that oxidative stress was stimulated in diabetic rats after STZ 
induction. These results are partially in agreement with a previous 
research in which investigators found that curcumin could inhibit 
lipid peroxidation and protect tissues from external damage in 
 glycemic rats [15].
Further studies have indicated that STZ can elicit a nonspecific islet 
inflammation and apoptosis in animals [16]. Bcl-2 protein family 
including proapoptotic Bax and caspases family play key roles in 
development of apoptosis under oxidative stress condition [16]. 
These sequences of events were observed in this study by immu-
noblot assay (Figure 3). Interestingly, DHM treatment markedly 
inhibited protein expressions of Bax and cleavage caspase-3, sug-
gesting that DHM could inhibit the activation of the apoptotic 
pathway (Figure 3). Moreover, DHM increased STZ-induced Bcl-2, 
further confirming that the protective effects of DHM are mediated 
by suppression of apoptosis.
Initiating the study in hepatocytes, we separated signaling effects 
of DHM on inflammatory signaling (Figure 4). Interestingly, we 
found that DHM as well as metformin significantly elevated protein 
Figure 5 | DHM decreased the phosphorylation of p38 and GSK-3b (Ty216) in the livers of rat. Relative density analysis of the (A) phospho-p38 and  
(B) phospho-GSK-3b (Ty216) protein bands. b-Actin was probed as an internal control in the relative density analysis. Data are shown as mean ± standard 
deviation; ##p < 0.01, compared with the control (normal) group; **p < 0.01, compared with the vehicle group (diabetic vs. normal group). N = 6 in each 
group. DHM, dihydromyricetin; Met, metformin.
A B
194 L. Chen et al. / eFood 1(2) 188–195
expression of AMPK. This mechanism is fully consistent with our 
other observations that metformin directly suppressed ROS and 
allergic eosinophilic inflammation via AMPK activation in mouse 
lung tissue [16]. Because TLR4, MyD88, and NF-kB activation, as 
well as AMPK modulation could mediate proinflammatory cyto-
kines expression, we next tested the expression of these proteins in 
liver tissues. As shown in Figure 4, diabetes was found to activate 
TLR4, MyD88, and NF-kB, and western blotting experiments have 
demonstrated that activation of expression of these proteins could 
be inhibited by administration of DHM at tested doses for 6 weeks. 
TLR4 could regulate inflammatory response through the MyD88 
pathway. Previous evidence has found that STZ exposure could 
induce diabetic liver injury via the TLR4/MyD88/NF-kB signaling 
pathway [17]. The inhibition of TLR4, MyD88, and NF-kB might 
be a critical step for the prevention of cascading inflammatory 
responses in complications of diabetes [17]. DHM was previously 
found to markedly inhibit inflammatory injury by inhibiting TLR4 
activation and subsequently suppressing the associated down-
stream signaling pathway of NF-kB [18]. Notably, metformin was 
proved to have the ability to inhibit liver NF-kB activation in dia-
betic rats under our experimental conditions. This result confirms 
the findings of Hou et al. [18], but is inconsistent with many other 
previous reports [1,4,7]. Overall, these results suggest that DHM 
exhibited protective effect against diabetes which may also occur 
partly by its action against diabetes-induced liver inflammation in 
the NF-kB-dependent pathway. TLR4 is another membrane-bound 
receptor that plays a critical role in the innate immune response.
In addition, p38 could regulate cellular properties in response to 
oxidative stress and inflammatory cytokines [19]. Both in vivo and 
in vitro evidence have suggested that p38 may be also involved in 
high-glucose-induced cellular hypertrophy [20]. Studies have also 
indicated that DHM reduces endotoxic inflammation via repressing 
ROS-mediated activation by suppressing p38 [21,22]. In the last 
section of this study, DHM was found to inhibit p38 expression 
and attenuate inflammatory-induced damage (Figure 5), suggest-
ing that DHM administration may have a critical role in prevent-
ing the progression of liver inflammatory diseases. Activation of 
Akt leads to inactivation of GSK-3b, which in turn enhances the 
expression of GS protein, potentially, on glucose transport activity. 
Inhibition of GSK-3 by the AMPK signaling pathway is involved 
in the regulation of the NF-kB activation and inflammatory path-
way [23]. Recently, DHM was proved to have protective effects 
on STZ-induced neurotoxicity by suppressing the regulation of 
GSK-3b/Nrf2 signaling [4]. DHM also elicits potent neuroprotec-
tive effects in a model of major depressive disorder by inhibiting 
GSK-3b activation [3]. In our animal model, phosphorylation of 
GSK-3b was stimulated after STZ induction, which might cause an 
inflammatory response in liver (Figure 5). However, DHM treat-
ment inhibited inflammation and suppressing the GSK-3b activity. 
These results provide the first evidence that DHM exerts protective 
effects on STZ-induced liver damage via the GSK-3b pathway.
5. CONCLUSION
In conclusion, DHM reversed STZ-induced hepatic impairments by 
suppressing oxidative stress, inflammation, and apoptosis (Figure 6). 
In particular, DHM ameliorated diabetic oxidative damage in the liver. 
DHM inhibited hepatic apoptosis by triggering the levels of Bcl, Bax, 
and cleaved caspase-3. Finally, DHM inhibited inflammatory response 
by modulating the TLR4, MyD88, AMPK, p38, and GSK-3b pathways.
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